NOD1 protein inhibiting polypeptide and application thereof

A protein inhibition, rheumatoid technology, applied in the field of medicine to achieve the effect of preventing or treating rheumatoid arthritis

Inactive Publication Date: 2015-11-04
SUZHOU PULUODA BIOLOGICAL SCI & TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no well-developed NOD1 protein inhibitory peptides have been developed for the treatment of RA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • NOD1 protein inhibiting polypeptide and application thereof
  • NOD1 protein inhibiting polypeptide and application thereof
  • NOD1 protein inhibiting polypeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Immunoprotective effect of NOD1 protein inhibitory polypeptide in collagen-induced mouse arthritis animal model

[0012] To construct collagen mouse arthritis animal model, and to study the therapeutic effect of NOD1 protein inhibitory polypeptide on collagen induced arthritis (CIA) in mice. Mice were used as experimental animals, 60 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab.Animal Ltd), animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, body weight 18-22g, were randomly divided into 6 groups, which were normal control group, model control group, 3 low, middle and high dosage groups of polypeptide (1, 2, 4mg / kg ) and positive drug control group (methotrexate 2mg / kg). Except the normal group, mice CIA models were established in each experimental group on the 0th day by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and overnight in a refrigerator at 4°C. On the day of...

Embodiment 2

[0020] Protective effect of NOD1 protein inhibitory polypeptide on the in vivo immune protection of adjuvanted rat arthritis animal model

[0021] An animal model of adjuvant arthritis in rats was constructed to study the therapeutic effect of the polypeptide on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 60 SPF grade SD rats (provided by Sino-British SIPPR Lab.Animal Ltd), animal production license number: SCXK (Shanghai) 2008 -0016), male, with a body weight of 140g-160g, were randomly divided into 6 groups, namely normal control group, model control group, NOD1 protein inhibitory polypeptide low, medium and high dosage groups (0.5, 1, 2mg / kg) and positive drug control group (methotrexate 1mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10mg / ml) in the left rear of the rat. 0.1ml caused rat a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, in particular to a polypeptide which has an NOD1 protein inhibiting function and can prevent or treat rheumatoid arthritis. The sequence of the polypeptide is MKNMWKSARKIDAFQHM and is brand-new; the polypeptide can be used for treating and preventing rheumatoid arthritis diseases in multiple administration modes including subcutaneous or intramuscular injection, intravenous injection or drip and oral administration in modes of pills, capsules, nasal spray and the like. The designed NOD1 protein inhibiting polypeptide is scientific, reasonable, feasible and effective, and can be used as the medicine for treating or preventing rheumatoid arthritis.

Description

Technical field: [0001] The present invention relates to the field of medicines, in particular to polypeptides for preventing and treating or preventing rheumatoid arthritis. Background technique: [0002] The etiology and pathogenesis of rheumatoid arthritis are not yet fully understood, mainly the body's immune response to the autoimmune system, causing inflammatory arthritis. With chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, it belongs to autoimmune inflammatory disease. The basic pathological features are vasculitis and synovitis. Intra-articular synovial blood vessels proliferate and form pannus, resulting in synovial thickening, increased exudation, secretion of various cytokines, invasion of cartilage and bone damage. It can also erode the surrounding muscle cavity, ligament, tendon sheath, muscle and other tissues, thereby affecting the stability of the joint, prone to joint deformity and dysfunction....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/08A61K38/10A61P19/02A61P29/00
Inventor 罗瑞雪
Owner SUZHOU PULUODA BIOLOGICAL SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap